Abstract. We aimed to examine the rate of thrombotic events after discontinuation of one year clopidogrel therapy in patients with implanted coronary stent, and to determine platelet aggregability by multiple electrode analyzer after cessation of clopidogrel. This prospective, multicenter study enrolled 200 patients subjected to coronary stent implantation and treated with aspirin + clopidogrel one year after the stent placement. Platelet aggregation was measured using 3 agonists [adenosine diphosphate with PGE 1 (ADPHS), arachidonic-acid (ASPI), and thrombin receptor activating peptide (TRAP)] on the day of cessation of clopidogrel and at 10, 45, and 90 days after clopidogrel was stopped. Two thrombotic events were registered during the 6-months follow up (one ischemic stroke and one myocardial infarction; incidence of 1%). The mean values of ADP + PGE 1 -and ASPI-induced aggregation 10 -90 days after the cessation of clopidogrel were significantly higher than values obtained before the termination of the drug (P < 0.001, all). Cessation of clopidogrel did not influence the TRAP-induced aggregation, which reached the plateau in all measurements. In conclusion, the incidence of thrombotic events after the cessation of one-year clopidogrel treatment might be lower than expected in patients with implanted coronary stent.
Introduction
Dual antiplatelet therapy (aspirin + clopidogrel) is an essential therapeutic regimen for the prevention of stent thrombosis after percutanous coronary intervention (PCI) (1 -5) . The optimal duration of such a therapy is still a matter of debate (6) . However, premature discontinuation of clopidogrel treatment was confirmed to be among the strongest predictors of stent thrombosis in patients with either bare-metal or drug-eluting stents (7, 8) . It is currently recommended that patients with drug-eluting stents (DES) and patients with acute coronary syndrome (ACS) who underwent PCI should receive dual antiplatelet therapy for at least a year (1, 2) .
Recent studies have shown that abrupt termination of long term use of clopidogrel may be associated with a "rebound" effect in patients with implanted coronary stents (9, 10) . Sudden withdrawal of long-term clopidogrel therapy in patients with ACS who underwent primary PCI was followed by adverse clinical events within 90 days after the cessation of such a treatment (11) . Accordingly, it is necessary to measure objectively the "rebound" effect (i.e., enhanced platelet activity) and to assess the relationship between such a phenomenon and the increased risk of adverse outcomes in patients with implanted stents after clopidogrel discontinuation. Unfortunately, the "rebound" effect is not well defined. It could mean a temporarily enhanced platelet aggregability after clopidogrel discontinuation and/or just a slow return of platelet function to normal values. The aim of our study was to assess the rate of the adverse cardiovascular events after abrupt, but "on time" cessation of one-year clopidogrel treatment in patients with coronary artery disease (CAD) who underwent PCI. Also, we tested the platelet function after termination of clopidogrel therapy by a multiplate electrode analyzer.
Materials and Methods

Study design
This prospective multicentric study enrolled 200 patients who underwent coronary stent implantation at the Clinical Centre of Serbia and Military Medical Academy, from September 2008 to March 2009. Half of those patients (n = 100) received a bare-metal stent (BMS), while the other half (n = 100) received a DES. Both groups of patients were treated with dual antiplatelet therapy (aspirin at 300 mg daily for the first month and 100 mg per day after that + clopidogrel at 75 mg/day) for one year after the implantation of stent(s). Clopidogrel treatment was subsequently stopped in both groups of patients after clinical and electrocardiographic (ECG) examination. Patients continued taking all other drugs that they used previously, including aspirin.
Exclusion criteria for enrollment were age ≤ 20 years and age > 80 years, thrombotic events during clopidogrel therapy, use of oral anticoagulant drugs, selected hematological abnormalities (hemoglobin < 100 g/l, platelet count < 100 × 10 9 cells/l or > 600 × 10 9 cells/l), malignancies, and chronic inflammatory diseases.
Blood samples
Blood samples from all patients (n = 200) were taken four times for Multiple Electrode Aggregometry (MEA). The first sample was taken on the day of cessation of clopidogrel (after taking the last tablet); a second sample was taken 10 days after termination of clopidogrel treatment. The third and fourth samples were taken 45 and 90 days after discontinuation of clopidogrel.
This nonintervention study was conducted according to the Declaration of Helsinki and was approved by the Ethics Committee of the School of Medicine, University of Belgrade, Serbia (license No 440/VI-12, from 19.06.2009 ).
Blood samples for platelet function testing were taken in the catheterization lab by atraumatic, venipuncture of the antecubital vein. Blood was collected into commercially available prefilled vacutainer tubes containing lithium-heparin as an anticoagulant (6.0 ml; BD Vacutainer, Plymouth, UK). Blood samples were kept at room temperature for at least 30 min and not more than 2 h before analysis.
MEA
Platelet aggregation was determined by a standardized impedance aggregometer (Multiplate ® analyzer; Dynabyte Medical, Munich, Germany), an instrument with five channels for parallel aggregometry measurements and an internal computer system for real-time analysis and documentation (12, 13) .
Pipetting is performed by means of an attached, software controlled electronic pipette, which enables the user to perform the analysis according to standardized operating procedures.
Each aggregometry test was performed with 300 μl of saline and 300 μl of heparinized blood pipetted into single-use test cell containing four metal, silver-covered electrodes that formed two independent sensor units. After 3 min of incubation and stirring at 37°C, the measurements were started by adding 20 μl of the appropriate agonist solution to the 1:1 diluted blood. The change of impedance, based on the aggregation process on the surface of electrodes within the sample was recorded continuously for 6 min. Since the change in impedance was measured simultaneously on two sensor units, the result of each test represented the mean value of the two aggregation curves obtained. The induced change in the impedance of the imposed electrical system is continuously recorded and plotted against time calculating the area under the curve (AUC). The AUC reduction corresponds with the extent of platelet inhibition.
To monitor drug-induced platelet inhibition, aggregation was stimulated with the following commercially available standardized reagents (Dynabyte): arachidonic acid, the substrate for cyclooxygenase (COX), which subsequently forms the potent platelet activator thromboxane A 2 (TXA2) (ASPI test, the final concentration 0.5 mM); adenosine diphosphate (ADP) in the presence of a low concentration of prostaglandin E 1 (PGE 1 ) which acts via ADP receptors (ADPHS test, the final concentration 6.5 μM); thrombin receptor activating peptide which acts via the thrombin receptor on the platelets surface (TRAP test, the final concentration 32 μM).
ADP-induced platelet activation requires the coordinate stimulation of both P2Y 1 and P2Y 12 receptors. Clopidogrel antagonizes the ADP effects via P2Y 12 receptors only, while P2Y 1 receptors remain unblocked. PGE 1 inhibits platelet aggregation by increasing intracellular cAMP levels, which may oppose the action of ADP on its unblocked P2Y 1 receptors (14) . Thus, the combination of ADP + PGE 1 (ADPHS test) is used to enhance sensitivity for the effect of clopidogrel on platelet aggregation (15) .
The manufacturer's reference values for blood donors (normal participants) are as follows: ASPI test 790 -1410 aggregation unit (AU) × min, ADPHS test 406 -992 AU × min and TRAP test 923 -1509 AU × min.
Study endpoints
The primary endpoint of the study was the incidence of thrombotic events (myocardial infarction, stroke, stent thrombosis) within follow-up period of 180 days after clopidogrel cessation. As secondary endpoint, we monitored the platelet aggregation (ASPI, ADPHS, and TRAP test) four times within 90 days after clopidogrel discontinuation, with a special emphasis on the ADPHS and TRAP test.
All patients (n = 200) underwent scheduled clinical and ECG examinations at the day of exclusion of clopidogrel and at 10, 45, and 90 days after discontinuation of this antiplatelet drug (Fig. 1) . Also, we made a phone interview at 180 day after termination of clopidogrel, and all the information was entered and stored into the computer database.
Statistical analyses
Sample size calculation for the present study was based on the data from the study of Ho et al. (9) where the rate of occurrence of adverse outcome was 4.7% in the first three months after termination of clopidogrel. Using α value of 0.05 and precision of 3%, the calculated sufficient sample size was 191.
Statistical analysis was performed using SPSS statistical software (SPSS for Windows, release 17.0; SPSS, Chicago, IL, USA). Descriptive statistics are presented as mean values with standard deviations for continuous variables. Categorical data are presented by absolute numbers with percentages. Differences between groups were compared with Student's t-test and Chi-square test. Changes in TRAP, ADPHS, and ASPI between different time periods (start, 10th, 45th, and 90th day) were determined by ANOVA for repeated measurements. In all tests, a P-value < 0.05 was considered to be statistically significant.
Results
Two hundred patients were included in the study, 100 with BMS and 100 with DES. Demographic and angiographic characteristics are shown in Table 1 . Patients with BMS had a higher incidence of previous myocardial infarction and had a lower incidence of previous angina and PCI as compared with patients with DES. In addition, among patients who received BMS, index PCI was more frequently performed during acute coronary syndrome, as primary or urgent PCI compared to the DES group. Also, the mean stent length was greater in the DES patient group. By analyzing our patients with DES it was observed that a sirolimus-coated stent was received by 59 patients and an everolimus-coated stent was received by 25, 16 patients were treated with a zotarolimuseluting coronary stent. No one received paclitaxel-coated stents. Other demographic and procedural characteristics were similar among the patients with BMS or DES.
All patients completed the 180-days follow-up. Two thrombotic events were recorded in all patients during this period (2/200; i.e., 1%). One patient with BMS had a fatal ischemic stroke within one month after discontinuation of clopidogrel. The other one with DES had acute myocardial infarction (AIM), 5 months and 15 days after termination of clopidogrel, and he was treated with primary PCI. However, the infarct-related artery in this case was the right coronary artery, while he had the DES stent on the left anterior descendent without restenosis or thrombosis. During the same follow-up period, two patients with BMS were subjected to coronary angiography due to a positive stress test or unstable angina, but without thrombotic events confirmed.
The results of platelet aggregation, which were measured by MEA in both groups of patients 4 times (at the day of exclusion of clopidogrel and at 10, 45, and 90 days after discontinuation of the drug) and for all three agonists used (arachidonic acid: ASPI test, ADP + PGE 1 : ADPHS test, and thrombin receptor-activating peptide: TRAP test) are given in Table 2 . Patterns of changes of platelet aggregation over time after the cessation of clopidogrel treatment are shown in Fig. 2 . The mean value of ADP + PGE 1 -induced aggregation (6.5 μM) before the termination of clopidogrel was significantly lower compared to the values at 10, 45, and 90 days after termination of clopidogrel (336.34 ± 149.29 vs. 751.61 ± 194.14, 790.89 ± 191.76, and 845.81 ± 179.69, respectively; P < 0.001 between the first value and all values after the termination of clopidogrel), which is expected since the effect of clopidogrel suppression of platelet activity was missing.
There were no significant differences in the mean values of TRAP-induced platelet aggregation at the day of the cessation of clopidogrel compared to the values after the cessation of clopidogrel (days 10, 45, and 90). 42 (21) 150 (75) 150 (75) 112 (56) 159 ( 23 (23) 69 (69) 22 (22) 71 (71) 74 (74) 61 (61) 95 (95) 28 (28) 8 (8) 72 (72) 28 (28) 1 (1) 52 ± 9.08
84 (84) 70 (70) 4 (4) 90 (90) 14 (14) 22 (22) 58 (58) 22.83 ± 5.28
3.32 ± 0.41
1.52 ± 0.77 56.78 ± 10.42
19 (19) 27.22 ± 3.07
24 (24) 76 (76) 20 (20) 79 (79) 76 (76) 51 (51) 64 (64) 57 (57) 23 (23) 12 (12) 88 (88) 4 (4) 53.78 ± 9.77
84 (84) 61 (61) 5 (5) 85 (85) 27 (27) 17 (17) 59 (59) 25.34 ± 6.57 There was no significant difference between the mean values of aggregation in patients with BMS compared to patients with DES, at the first measurement (while patients are still receiving clopidogrel) and at 10, 45, and 90 days after its exclusion, for all agonists used (Table  2) .
Of note, two patients with thrombotic events were clopidogrel responders as well (ADPHS values of 313 and 270 AU × min in patients with BMS and DES, respectively). After the discontinuation of clopidogrel, the increase in ADPHS values was observed in both cases (patient with BMS, day 10, value of 597 AU × min; patient with DES, days 10, 45, and 90, values of 800, 1176, and 1106 AU × min, respectively).
Discussion
Our study shows that the incidence of thrombotic events after the abrupt termination of long-term (1 year) clopidogrel treatment in patients with CAD subjected to stent implantation is lower than expected.
Some clinical trials have shown that premature discontinuation of clopidogrel may be associated with high incidence of adverse outcomes. The adverse effects reported in those early trials mainly occurred when clopidogrel treatment was stopped less than 12 months after the stent placement (16 -19) . However, our patients received clopidogrel therapy for 12 months after PCI, so we cannot discuss the adverse outcomes after premature termination of the drug. One could argue that a cluster of adverse events could be just postponed in our patients subjected to long-term clopidogrel treatment, but even such delayed thrombotic outcomes would be more probably due to atherothrombosis itself, but not to the exaggerated platelet function after cessation of clopidogrel.
In a recent retrospective cohort study on 3137 patients with acute coronary syndrome, Ho et al. (9) observed a clustering of adverse events in the initial 90 days after cessation of clopidogrel among both medically-treated and PCI-treated patients. Participants were treated with clopidogrel from 3 to more than 12 months, and the inci- Multiple Electrode Aggregometry (MEA) tests were performed on the day of cessation of clopidogrel and at 10, 45, and 90 days after clopidogrel was stopped (measurements 1, 2, 3, and 4, respectively). AU = aggregation units. *P < 0.001: compared to the result of the next measurement. dence rate ratios for primary endpoint outcomes were adjusted for confounding by clopidogrel treatment duration. The combined end point of all-cause mortality or AMI occurred in 4.7% (73/1569) of the patients from the PCI group within 90 days. As previously mentioned, our study demonstrates that in patients with implanted coronary stent (BMS or DES), abrupt discontinuation of long-term use of clopidogrel (12 months) was not associated with a significantly increased rate of thrombotic events. The primary endpoint events were observed only in two patients within 180 days after the cessation of clopidogrel treatment (1%). Neither patient had stent thrombosis. According to Academic Research Consortium (ARC) criteria, a patient with AMI would be categorized as probable stent thrombosis if primary angioplasty had not been performed on him during the second event. This means that we overestimate incidence of stent thrombosis using this criteria and that progression of atherosclerotic lesions at other locations might be responsible for the thrombotic event, as we had in our patient.
In addition, stable coronary artery disease predominates in our patients and that could possibly explain the low incidence of adverse outcomes observed. The other reason for the low incidence of stent thrombosis in patients with DES stents was that no one received paclitaxel-eluting stents, which has a little higher frequency of stent thrombosis than the DES stents used in this study (20 -22) .
Because the study of Ho et al. spanned the time when drug-eluting stents were first introduced, only a minority of their patients had received a drug-eluting stent, so that we are not able to compare our results with them in terms of outcomes in relation to the type of stent.
Also, we determined ASPI-induced platelet aggregation to exclude the potential impact on inadequate response to aspirin on the occurrence of adverse outcomes and to make sure that the eventual thrombotic events are due to discontinuation of clopidogrel. The "rebound" effect itself may contribute to the increase in thrombotic outcomes after withdrawal of clopidogrel. However, the clopidogrel treatment cessation-caused "rebound" phenomenon is not unequivocally defined and explained, although it might be related to an intermittent status of platelet hyperreactivity with very high ADP-induced platelet aggregation levels (23, 24) .
A methodology similar to ours was applied in the study of Mylotte et al. (25) in which platelet aggregation was measured at 1 week, 1 month, and 3 months after clopidogrel discontinuation, using a modification of light transmission aggregometry in response to multiple concentrations of ADP, epinephrine, arachidonic acid, thrombin receptor-activating peptide, and collagen. The study used a relatively low number of participants which preclude valid analysis of clinical end-points; however, the results showed a transient increase in platelet reactivity 1 month after clopidogrel withdrawal.
There was not any rebound effect regarding platelet aggregation 10 -90 days after the cessation of clopidogrel since MEA values reached the plateau with all agonists (Fig. 2) . Similar results were shown by Sibbing et al (23) .
It should be noted that the TRAP-induced aggregation is not sensitive towards a blockade of COX by aspirin or the ADP receptor by clopidogrel, but this measurement shows well the response to one of the most important platelet agonist -thrombin. Our results have shown normal steady platelet aggregation to thrombin without any significant variation after cessation of clopidogrel, which may be an indication that the "rebound" effect does not exist.
Nevertheless, we could not reach a firm conclusion about the individual platelet hyper-reactivity in our patients. Such a limitation of our study is mainly due to our inability to measure initial, baseline values of platelet aggregation (before the introduction of clopidogrel). It is known that patients who come to the catheterization unit must be prepared for intervention with dual antiplatelet therapy, so practically it is almost impossible to determine this value. The absence of the baseline level of aggregation prevents a clear distinction between return to the level before the introduction of drugs or platelet hyper-reactivity. Such a baseline value of platelet aggregation was reported in the PACT study (26) , which showed that the abolition of clopidogrel leads to recovery of platelet reactivity to pretreatment levels but not rebound platelet hyper-reactivity. However, the study was conducted on healthy volunteers, so the results cannot be extrapolated to cardiovascular patients who usually have a modified platelet function in comparison to healthy subjects.
Also, we found that clopidogrel inhibited ASPIinduced aggregation. It is known that ADP increases synthesis of TXA2, and clopidogrel and aspirin have a synergistic effect on TXA2-mediated platelet activation. Accordingly, cessation of clopidogrel may enhance TXA2 production, attenuate the response to aspirin, and increase ASPI values.
Considering all relevant facts relating to the "rebound" effect, it is clear that no matter if its existence is proven in the laboratory, it is important to establish the existence of "clinical rebound", in other words, the occurrence of adverse cardiovascular outcomes. In addition, abrupt discontinuation of one-year clopidogrel treatment is probably not followed by clinically significant rebound phenomenon.
